A significant portion of cancer patients are initially diagnosed with localized disease and are eligible for curative interventions. However, residual tumors cells, representing molecular residual disease (MRD), remaining after these interventions might result in disease recurrence.

In solid tumors without routine HER2 expression assessment and no approved anti-HER2 treatments, comprehensive genomic profiling (CGP) is crucial, as it not only helps determine eligibility for existing targeted therapies but also identifies genomic ERBB2 alterations that could respond to emerging anti-HER2 antibody-drug conjugates in clinical dev

Labcorp® Plasma Complete™ is a comprehensive next generation sequencing (NGS), cell free DNA profiling test that identifies clinically relevant variants in advanced and metastatic solid tumors across 521 genes as well as microsatellite instability (MSI).

PGDx elio™ Tissue Complete (ETC) is a comprehensive tumor profiling next generation sequencing (NGS) kitted solution. NGS-based solutions often involve complex protocols with multiple touchpoints that might benefit from automation.

The PGDx elio™ Plasma Focus Dx is a highly specific, sensitive, reproducible, and accurate hybrid capture-based next-generation sequencing (NGS) assay optimized for cell-free DNA with excellent performance in analytical validation studies across various variant types and solid tumor types.

The Labcorp Plasma Focus test demonstrated a 95.8% success rate and was able to detect clinically actionable variants across various cancer types, with rapid reporting for the majority of cases, highlighting its effectiveness in informing precision oncology decision-making.

The TSO500 HT assay has been effectively validated to genotype HLA-A, -B, and -C from tumor samples, providing valuable tumor-informed HLA allele haplotypes with high accuracy, which can aid clinicians and drug developers in selecting HLA-directed therapies and enrolling patients in HLA-restricted clinical trials across various tumor types, includ

The use of LAG-3 expression as a clinical biomarker to select for patients who might benefit from anti-LAG-3 immuniotherapies might require multiple rapid, sensitive, and accurate assays.

Non-V600 BRAF mutated melanomas, compared to those with BRAF V600 mutations or BRAF WT tumors, had higher levels of immune cell infiltration, increased tumor mutation burden (TMB), and elevated expression of immune checkpoint and T cell exhaustion markers, indicating a potentially favorable response to combination immune checkpoint inhibitors (ICP

This study developed and validated a workflow for accurately determining the genetically inferred ancestry (GIA) of patients from comprehensive genomic profiling (CGP) sequencing results, which can enable ancestry-aware biomarker research and contribute to reducing cancer disparities and improving representation in clinical trials.